Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms(LUTS) Due to Benign Prostatic Hypertrophy (BPH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2021
Price :
$35
*
At a glance
- Drugs Ozarelix (Primary)
- Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 30 Sep 2021 Phase of this trial is changed from phase 2/3 to phase 2.
- 07 Jun 2012 Actual patient number is 76 according to ClinicalTrials.gov.
- 12 Jan 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.